When cancer treatment ends, hope begins – but for many, so does uncertainty. Digital PCR based assays can detect DNA fragments shed by tumors in the blood to monitor minimal residual disease. Such tests can help pharmaceutical companies develop drugs more quickly, and offer clinicians a powerful early warning system of cancer relapse.
Early cancer detection with liquid biopsy
Imaging shows the big picture every few months, but what if you could see a cancer’s next move in real time? dPCR liquid can reveal recurrence long before scans do.
MRD monitoring and using ctDNA is in its infancy, but it's also at a really interesting Inflexion point where clinical utility is starting to build up. We see ourselves enabling the adoption of this technology and we truly believe that the benefits will be universal for cancer patients in the clinic.
Mark Kaganovich, Co-founder, Tracer Biotechnologies
Bios
Gopal Ramachandran
Gopal Ramachandran is the co-founder and Chief Scientific Officer of Tracer Biotechnologies. Previously he served as Chief Technology Officer of Wellframe (acquired by Blackstone). Ramachandran completed his postdoctoral work at the Broad Institute and received his PhD in Mathematics from MIT and MD from Harvard Medical School.
Mark Kaganovich
Prior to co-founding Tracer Biotechnologies, Mark Kaganovich was the Chief Executive Officer and co-founder of SolveBio (acquired by Precision Medicine Group). Kaganovich received his PhD in Genetics from Stanford University and a Bachelor’s degree in Biochemistry and Computer Science from Harvard University.
October 2025